Benjamin L. Palleiko
2023
In 2023, Benjamin L. Palleiko earned a total compensation of $2.4M as President, Chief Business Officer and Chief Financial Officer at Carbylan Therapeutics, a 29% decrease compared to previous year.
Compensation breakdown
| Bonus | $180,075 |
|---|---|
| Option Awards | $189,421 |
| Salary | $514,500 |
| Stock Awards | $1,524,224 |
| Other | $12,527 |
| Total | $2,420,747 |
Palleiko received $1.5M in stock awards, accounting for 63% of the total pay in 2023.
Palleiko also received $180.1K in bonus, $189.4K in option awards, $514.5K in salary and $12.5K in other compensation.
Rankings
In 2023, Benjamin L. Palleiko's compensation ranked 417th out of 3,006 executives tracked by ExecPay. In other words, Palleiko earned more than 86.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 417 out of 3,006 | 86th |
Division Manufacturing | 237 out of 1,650 | 86th |
Major group Chemicals And Allied Products | 167 out of 918 | 82nd |
Industry group Drugs | 164 out of 881 | 81st |
Industry Pharmaceutical Preparations | 102 out of 637 | 84th |
Source: SEC filing on August 14, 2023.
Palleiko's colleagues
We found two more compensation records of executives who worked with Benjamin L. Palleiko at Carbylan Therapeutics in 2023.